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Abstract 
Hydroxyurea (HU) has been shown to be effective in 
alleviating the symptoms of Sickle Cell Anemia disease. 
While Hydroxyurea reduces the complications associated 
with Sickle Cell Anemia in some patients, others do not 
benefit from this drug and experience deleterious effects 
since it is also a chemotherapeutic agent. Therefore, to 
whom, should the administration of HU be considered as a 
viable option, is the main question asked by the responsible 
physician.  We address this question by developing modeling 
techniques that can predict a patient’s response to HU and 
therefore spare the non-responsive patients from the 
unnecessary effects of HU. We analyzed the effects of HU on 
the values of 22 parameters that can be obtained from blood 
samples in 122 patients. Using this data, we developed Deep 
Artificial Neural Network models that can predict with 92.6% 
accuracy, the final HbF value of a subject after undergoing 
HU therapy. Our current studies are focusing on forecasting 
a patient’s HbF response, 30 days ahead of time. 
Key words: Artificial, Neural, Network, Deep, Sickle, 
Cell, Anemia, predictive. 
1. Introduction 
Sickle cell anemia is an inherited form of anemia, a 
condition in which there is not enough healthy red blood cells 
to carry adequate oxygen throughout the body. Red blood 
cells contain the oxygen-carrying molecule called 
Hemoglobin (Hb) which are of different types depending on 
the composing sub-units. Sickle cell disease patients have the 
Sickle Hemoglobin (HbSS) sub-unit, which does not carry 
the amount of oxygen needed. Fetal Hemoglobin (HbF) is 
another sub-unit that is normally lost as we age but is not 
subject to the mutation that causes Sickle Cell Anemia 
(SCA). Hydroxyurea has been observed to increase the 
amount of HbF in circulation. Most patients respond to 
Hydroxyurea (HU) therapy with an increase in the HbF 
concentration of blood [1], therefore reducing the number of 
incidents related to Sickle Cell Anemia. Although 
Hydroxyurea, in general, reduces the number of 
complications of the SCA disease in most patients, it has 
numerous deleterious effects since it is an agent used during 
chemotherapy. Therefore, the primary challenge facing a 
physician who is providing care to an SCA patient is whether 
the benefits of the HU outweigh its detriments. In the absence 
of any prior knowledge, a trial process of more than six 
months is initiated in order to determine a patient’s response 
to potentially a harmful treatment. 
Pattern recognition and value prediction techniques based 
on the employment of artificial neural networks have had 
great success especially in establishing complex 
relationships and identifying patterns between disparate 
parameters such as age, gender or genetic information. 
Artificial Intelligence tools, including Deep Neural 
Networks (DNN), have historically been used in the 
development of Clinical Decision Support [2], medical 
image processing [3][4], and prediction of patient outcomes 
[5][6].  
Availability of predictive tools can be of paramount 
importance in the development of personalized medicine. 
More specific to the SCA, if the magnitude of the HU-elicited 
increase in the percentage fetal hemoglobin in a patient with 
sickle cell anemia can be predicted, it will aid in the 
identification of responders and non-responders to the 
therapy, non-compliant patients, and an estimation of the 
extent of response for the identified responders [7]. This 
approach could also give physicians the incredibly important 
ability of predicting whether a patient’s sickle cell 
symptom(s) will be significantly reduced by the therapy. 
Having the ability to look at a patient on an individual basis 
and being capable of determining if the projected benefits of 
treatment are worth the deleterious side effects that could 
ensue, will allow for a more specific patient guided therapy. 
Previous work [5] reported the utility of ANN in predicting 
the effectiveness of Hydroxyurea therapy for Sickle cell 
anemia patients. In that report, a shallow ANN was used to 
identify HU treatment responders using a limited definition 
of responders. Here we continue our previous work by 
establishing the use of ANN in a more pragmatic definition 
of responders as patients who more than double their initial 
%HbF. We also perform additional data analytics in order to 
expose the challenging nature of this dataset. Finally, we 
provide a preliminary report on the utilization of LSTM [8] 
to predict a patient’s response to HU one month in advance.  
2. Background 
Sickle Cell Disease/Anemia is an autosomal recessive 
genetic disease where Red Blood Cells (RBC’s) take the 
 shape of a crescent/sickle. Sickle cell mutation is a non-
conservative missense mutation where the Glutamate 
(hydrophilic) in the  6th amino acid of the beta globin is 
substituted with a Valine (hydrophobic). A hemoglobin 
tetramer which is 2- alpha and 2-mutated beta is called Sickle 
Hemoglobin (HbS). HbS is able to carry oxygen, but when 
deoxygenated, it changes its shape, making it capable of 
clustering with other HbS complexes that form polymers and 
distort the shape of red blood cells into a crescent shape 
(Sickling)[9].This change allows the easier destruction of 
erythrocytes, causing anemia, among other things [10]. 
Hydroxyurea (Hydrea or HU) is a preventive medication 
that reduces the complications associated with Sickle Cell 
Anemia (SCA). HU operates by increasing the amount of 
gamma-globin in the RBCs which results in the expression 
of more fetal hemoglobin (HbF) that is not subject to Sickle 
Cell mutation. HbF is the primary Hemoglobin during the 
fetal development stages and at birth, which explains why 
Sickle cell symptoms do not appear until a few months of life 
(when adult Hb, containing the mutated beta globin starts to 
dominate) [11].  
As with all medications, positive response is not 
guaranteed; some patients respond positively depicted by an 
increase in the concentration of their fetal hemoglobin, while 
other patients do not respond positively (see fig 1). While 
Hydrea reduces the complications associated with SCA, it is 
a chemotherapeutic agent and may elicit the following side 
effects: nausea, vomiting, diarrhea or constipation, acute 
pulmonary reactions, genetic mutation, secondary leukemia, 
and hair loss, to name a few [12] . It is therefore beneficial to 
spare the non-responding patients from the unnecessary 
exposure to this drug’s side effects. 
In previous work [5], ANNs have been utilized to predict 
SCA patients responsiveness by way of a classification 
model, which categorizes patients into responders and non-
responders. the criteria employed for classification of 
responders consisted of patients whose HbF concentration 
exceeded the 15% threshold. Based on this definition of a 
responder, a person whose %HbF increased from an initial 
value of 14.9 to a final value of 15.1 is considered a 
responder. In contrast, a person whose %HbF increased from 
an initial value of 1.0 to a final value of 14.8 is considered a 
non-responder. Based on similar observations, the 
community has scrutinized the definition of a responder, and 
new definitions have been proposed. In this work, we explore 
the usability of ANN as a predictive tool for the early 
identification of responders based on different criteria. In 
addition, we present a new approach in utilizing the 
predictive power of Machine Learning techniques that allows 
us to remain agnostic to the definition of a responder.  
3. Materials and/or Methods 
3.1. Sickle Cell Anemia Patient Data 
In this experiment, data from 122 sickle cell anemia 
patients were collected over a varying period, depending on 
the patient’s response to the treatment and adherence to the 
project protocol. The cohort of patients were at least 16 years 
of age, who were treated with a daily, oral dose (based on 
body weight) of Hydroxyurea with subsequent increase in 
dosage if the HbF levels stabilized in successive monthly 
visits. Only patients who had received HU for 8 months or 
longer were included in the ANN experiments, although, 
certain patients began to display positive response well after 
8 months of continuous treatment. 
Blood samples were obtained and analyzed monthly. The 
values of 22 parameters [5] for each of the 122 patients were 
recorded for a minimum of 8 months and a maximum of 98 
months. The parameters analyzed for each patient are those 
normally included in a Complete Blood Count (CBC), 
Chemistry Profile (SMA18) serial HbF levels (absolute and 
percent), DNA analyses for globin gene haplotype and the 
number of genes, treatment duration, weight, age, and 
gender. The values of these parameters were used to train 
ANNs and for statistical analyses [5]. 
3.2. Statistical Analyses 
Our initial step in understanding the complexity of this 
study consisted of performing several standard analytics of 
the data. In addition to performing the first and second-
ranked statistical analyses, density estimation, principal 
component analysis, and correlation coefficient analysis 
were performed on the entire dataset. 
Density estimation [13] aims to visualize the effects of HU 
on patients who undergo the therapy by observing the 
distribution of HbF before and after the therapy across the 
entire cohort of participants.  
Principal component analysis [14] aims to explore 
meaningful strategies in performing dimensional-reduction 
in the principal component space to remove the unnecessary 
complexities of the problem. Correlation coefficient [14] , on 
the other hand, will be useful in reducing the dimensionality 
of the problem in the original parameter space by identifying 
the data with degree of correlation. 
3.3. Artificial neural networks approach 
This project utilized Artificial Neural Networks [15] 
(ANN) as the primary predictive Machine Learning 
approach. Our utilization of ANNs as the core predictive tool 
is based on the minimalist approach of employing the 
simplest model that will satisfy the problem requirements. 
Therefore, our investigations utilized a spectrum of ANN 
architectures including the legacy shallow ANNs. Our 
developments included neural network models using 
MATLAB [16]; or TensorFlow [17] and Keras [18].  
Within the dataset, some patients did not have complete 
values for all 22 parameters.  In this work, the missing data 
were substituted with a zero since it has no contribution to 
the updated weights during the learning process of the back-
propagation algorithm. A Shift of one was added to all data 
with a legitimate value of 0 (e.g. number of BAN). In 
addition, the dataset contained data with substantially 
different ranges. For instance, the age of the patient is 
measured in days (range was in thousands), while other 
 parameters such as haplotypes units have single digit values. 
This disparity in the range of data is automatically resolved 
by normalization of data in MATLAB during the 
training/testing processes.  
Due to the limited amount of data, we employed an n-fold 
cross validation approach; train with n-1, test with 1, repeat 
n times, where n is the total number of patients in the dataset. 
This approach was applied for all experiments conducted in 
this study. The details related to the optimal network 
architecture and the training-testing processes are discussed 
in the individual results sections.  
3.4. Specific aims of the project 
After data preprocessing, we explored the development of 
neural network models to carry out the following three aims. 
3.4.1. Aim 1: Classify responders and non-responders. 
We developed a shallow two-stage fully connected, feed-
forward artificial neural network topology in MATLAB with 
a backpropagation learning algorithm for training and 
testing. 
 Patients whose post-therapy HbF experienced a 15% 
increase or more were classified as responders and anyone 
whose values did not meet that threshold were classified as 
non-responders. This was performed as a repetition of earlier 
work[19], [20] to establish comparability in results and 
further ensure the integrity of results. 72 of the total 122 
patients with the highest number of observations were used 
for this experiment. 
  Due to the lack of general agreement on the specific 
percentage regarded as responding, we established a 
threshold for a positive response as patients who experience 
a HbF increase of 100% (double the initial HbF) or more 
because of its popularity among the community of Sickle 
Cell Anemia (SCA) researchers. 
3.4.2. Aim 2: Predict final fetal hemoglobin level. After the 
initial results obtained from implementing a shallow neural 
network in MATLAB for classifying responders and non-
responders, the next step is to attempt predicting a patient’s 
final fetal hemoglobin value after undergoing Hydroxyurea 
therapy. This is to predict the highest %HbF observed over 
the course of medication administration. 
Figure 1. Diagram of a feedforward Artificial Neural 
Network 
3.4.3. Aim 3: Prediction of %HbF one month ahead. 
Although it may be of theoretical benefit to gain prior 
knowledge of a patient’s maximum response to HU therapy 
(from Aim 2), such information is of little pragmatic use 
without knowing when the effect will be observed (in 6 
months or 6 years of therapy). To resolve this limitation we 
have explored a new approach where we can predict a 
patient’s %HbF one month in advance as a preliminary step 
toward predicting the time when the full effect of the 
medication will be observed. To that end, we implemented a 
recurrent neural network (RNN) with Long short-term 
memory (LSTM) for the time series prediction. 
A recurrent neural network is a class of artificial neural 
network where connections between nodes form a directed 
graph along a temporal sequence. LSTM networks are well-
suited to making predictions based on time series data, since 
there can be lags of unknown duration between important 
events in a time series, as is the case with the problem at hand 
[21], [22].  
 
 
Figure 2: Diagram of an LSTM Neural Network 
Regular feed-forward and recurrent deep neural network 
were developed using TensorFlow (an interface for 
expressing and executing machine learning algorithms) and 
Keras (Python machine learning application programming 
interface, which allows you to easily run neural networks). 
Training and testing were performed using the patient data 
previously obtained after pre-processing. The neural network 
architecture was regularly modified to obtain the optimal 
model. 
The neural network model used for the final HbF 
prediction was a deep model constituting 3 hidden layers. 21 
input neurons, 12 neurons for the first hidden layer, 8 neurons 
for the second hidden layer, 4 neurons for the third hidden 
layer and then a single neuron at the output layer (21-12-8-4-
1) since just the single value prediction is expected. 
We made use of the Adam optimizer for iterative update 
of the network weights and for each layer within the model, 
we made use of the rectified linear unit (ReLU) activation 
function with exception to the final layer which has a linear 
activation function because the output is expected to be a 
continuous value. This network architecture was used to 
predict the final fetal hemoglobin value after treatment. 
The neural network model used for the periodic prediction 
was a recurrent LSTM model. The data was prepared by 
normalizing the features and framing the dataset as a 
supervised learning problem as predicting the HbF response 
at the current month given the response and patient biological 
data from the previous month. The first input layer 
constitutes 50 neurons and 1 neuron in the output layer. The 
 input shape is 1 time-step with 22 features, because the input 
layer receives the 21 parameter values of the current time-
step and the resultant prediction of the previous time-step. 
4. Results and discussion 
4.1. Statistical analyses 
   As the first step in conveying the complexity of the 
problem, Figure 3 illustrates some examples of patient 
responses to the HU treatment. As illustrated in these figures, 
not all patients’ response to HU results in a monotonically 
increasing levels of HbF. Furthermore, it is evident that in 
some instances, an initial period of response follows by a 
decline in the HbF levels. Visual inspection of these response 
profiles, demonstrates the complexity of predicting a 
patient’s response to HU treatment.  
 
Figure 3.  Plots showing the varying response of different 
patient’s Fetal Hemoglobin to Hydroxyurea 
  Application of density estimation provides supporting 
evidence for the effectiveness of HU. Figure 4 shows the 
distribution of %HbF across all patients before (depicted 
with a continuous line) and after (depicted with a dashed 
line) the Hydroxyurea therapy. The vertical lines (in Figure 
4) correspond  to the mean values for each distribution. It is 
evident from this figure that there is a clear increase in the 
%HbF for most patients. In fact, the figure shows a notable 
increase in the average HbF value of the patients in the 
population. Furthermore, the distortion in the distribution of 
the %HbF before and after the HU therapy, indicates that 
patients exhibit an unequal response to the drug. One-tailed 
student T-test was applied to the results of statistical analyses 
to confirm that the observed variation in concentration of 
HbF, as well as other results, were due to the HU 
administered and not due to random events. A confidence 
level of 0.001 was the minimum value accepted as 
significant in the results of Student T-tests.  
 
Figure 4. Density distribution of SCA patients %HbF 
before and after undergoing hydroxyurea therapy 
   The correlation coefficient analysis results are shown in the 
heat map (shown in Figure 5). As shown in this figure, the 
22 parameters of this problem show correlation values within 
the mid range of -0.5 to 0.5, indicating that there is no 
substantial correlation between any two parameters in the 
dataset to assist with dimensional reduction. 
 
Figure 5. Correlation coefficient heatmap of all 
parameters in the patient dataset 
   Finally, the results of the spectral analysis obtained from 
principal component analysis are summarized in Figure 6. 
Based on the gradual decrease in the spectral analysis, it can 
be concluded that dimensional reduction in the principal 
component space is not a very effective approach.  
  
Figure 6. Spectral analysis from Principal Component 
Analysis conducted on the patient dataset 
In summary, the collective results of the statistical analyses 
exposes the complexity of the problem statement and 
suggests that the problem could benefit from the application 
of artificial neural networks. 
4.2. Results for Aim 1  
The neural network that was utilized during this 
experiment consisted of a single hidden layer with 4 hidden 
neurons. This ANN was able to identify responders and non-
responders based on the previously reported 15% threshold, 
with 83 percent accuracy. Although redundant, the repeat of 
the previous results was necessary to establish equality and 
continuity between the current and past work. A total of 72 
patients were used for this study and 60 of them were 
accurately classified by the neural network.   
The classification experiment was repeated with the same 
ANN topology using the doubling of %HbF criterion as the 
identification of responders. During this experiment, 98 of 
122 patients were predicted correctly producing a final 
accuracy of 80.5%. Specificity (the percentage of responders 
which were actually predicted as responders) was 88.5% and 
sensitivity (the number of responders which were predicted 
to be non-responders) was 60%. In general  the performance 
of this network indicated a slight bias towards prediction of 
responders.  
4.3. Results for Aim 2 
Predicting the final value of a patient’s HbF concentration 
allows the data analysts to avoid the lack of consensus within 
the community of physicians and caregivers. In this mode, 
we can simply predict the final %HbF value that a patient 
will achieve, and allow the physician’s to justify the use of 
HU. Restatement of the problem turns the problem definition 
from a classification problem to regression problem. The 
model will be predicting a real continuous value and this 
experiment was performed on the total dataset comprising of 
122 patients. During this study we utilized a neural network 
with 3 hidden layers and 24 (12-8-4) total neurons , which 
was modelled with TensorFlow and Keras. 
 Experimentation was carried out using all 122 patient data 
for training and testing. During the evaluation step, we used 
a percentage error threshold of 30% between the predicted 
value and the actual value. That is, if the actual value is 10 
and the predicted value (P) is greater than or equal to 7 and 
less than or equal to 13, it is considered correct, else, the 
prediction is considered false. With this approach to 
evaluation, 113 of the 122 predictions were correct giving a 
92.6% accuracy level. 
 
Figure 7: Predicted HbF value and their corresponding 
Actual Values 
 
 
Figure 8: Percentage Error Distribution of all ANN 
results 
4.4. Results of Aim 3 
Although the reformulation of the problem from 
classification into regression domain alleviates the 
dependency on the accepted definition of a responder, it does 
not remove other existing logistical limitations. For instance, 
while the regression approach may predict correctly the 
maximum achievable value of %HbF, it fails to provide the 
conditions under which such outcomes can be achieved. 
Some of the critical values that may be required in this 
prediction are the drug dosage and the time needed for the 
HU therapy to take the maximum effect. Here we present the 
results of a preliminary approach that allows prediction of 
 %HbF for a given patient 30 days ahead of time. In this 
exercise we employed the use of LSTM networks (modelled 
in TensorFlow and Keras) on a small subset of patients. This 
was performed as a series of regression problems (depending 
on the number of months the patient underwent therapy) with 
continuous output values at each step.  
For each patient, we used a series of expected values 
reflecting the next month’s HbF value. The monthly 
predictions are expected to follow the same sequence of 
progression or decline to be considered a successful 
prediction. 
    The Pearson’s correlation coefficient [14] (PCC) was used 
as a metric to determine the similarity in the monthly 
progression of the patient’s predicted and the expected HbF 
values. The results corresponding to our six preliminar 
patients are shown in Figure 9. In this figure, trends 
illustrated in red and green correspond to the actual and the 
predicted response trajectories of the six test patients 
respectively. Four of these patients exhibited PCC between 
0.6-1, 1 patient exhibited PCC in the intermediate range of 
0.3-0.59, and the remaining patient exhibited poor PCC score 
(less than 0.29).  
 The training process consisted of utilizing monthly 
observations across 121 subjects. The testing process 
consisted of obtaining the next predicted value of HbF for the 
excluded patient over the course of their therapy. This 
process was repeated for 6 patients.  
 
Figure 9: Some Sample patients time-series results predicted with with the LSTM neural network.(HbF on the Y-axis and 
Timestep in months on the x-axis)
 5.  Conclusion 
Neural networks are capable of recognizing patterns and 
complex relationships between parameters which are not 
easily discernible by man unaided by a machine. The 
parameter values used for this experiment were obtained 
before and after the patients underwent Hydroxyurea 
therapy. 
We have demonstrated that we can (with 83% accuracy) 
identify patients that will respond to Hydroxyurea (HU) 
therapy. We have been successful at predicting (with 92.6% 
accuracy) a patient's final fetal hemoglobin value after 
undergoing HU therapy such that the percentage error 
between the actual value and the predicted value is less than 
or equal to 30%. To improve the confidence in the model’s 
prediction, we have gone a step further with an 81.96%  
accuracy within a 15% error margin of expected and actual 
HbF values. 
Regardless of the way the output classes are categorized, 
training ANNs to accurately distinguish between different 
classes of patients is of value to the medical community. This 
experiment shows that ANNs are capable of exploiting 
correlations between medical data that physicians are not 
able to identify unaided. This approach and others like it will 
positively influence medical decision making, administration 
of intervention procedures and improve the practice of 
precision medicine. 
We have also demonstrated the potential for using a single, 
well trained general model to predict the response trajectory 
of a Sickle Cell Anemia (SCA) patient to Hydroxyurea (HU) 
with 60% accuracy.  
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